The Starr-Edwards caged-ball valve (SECBV) was first implanted on a man in September 21, 1960 [1]. A design breakthrough was achieved by Starr and Edwards, who engineered an integrated structure consisting of a stainless-steel cage, a fixation ring made from knitted Teflon cloth, and a heatcured Silastic ball. Design criteria were formulated. The materials had to be chemically inert, compatible with human tissue, atrumatic to blood, and nonthrombogenic. They also had to retain their structural properties over many years and lend themselves to being engineered into a valve that was acceptable to patients, opened and closed rapidly in response to changes in the pressure gradient, and resulted in limited obstruction to forward flow and minimal regurgitation in the closed position. Finally, it had to be technically feasible to implant the prosthesis securely in an appropriate physiologic position [2] .
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The Starr-Edwards caged-ball valve (SECBV) was first implanted on a man in September 21, 1960 [1] . A design breakthrough was achieved by Starr and Edwards, who engineered an integrated structure consisting of a stainless-steel cage, a fixation ring made from knitted Teflon cloth, and a heatcured Silastic ball. Design criteria were formulated. The materials had to be chemically inert, compatible with human tissue, atrumatic to blood, and nonthrombogenic. They also had to retain their structural properties over many years and lend themselves to being engineered into a valve that was acceptable to patients, opened and closed rapidly in response to changes in the pressure gradient, and resulted in limited obstruction to forward flow and minimal regurgitation in the closed position. Finally, it had to be technically feasible to implant the prosthesis securely in an appropriate physiologic position [2] .
Hemodynamic performance -data from Marrow et al. [3] -provides satisfactory conditions at rest and exercise, although the projection of the mitral valve prosthesis into the left ventricular chamber can produce outflow obstruction.The main advantage of the SECBV is its proven durability. We present a case of mitral valve (SECBV) replacement survived 39 years.
Case report
A 57-year-old woman presented with rheumatic fever when she was 9 years old (1954) and she had recurrence when she was 12 and 15 years old. When she was 17 years old (1962) she suffered from heart failure. At 23 years (functional class IV NYHA) she underwent an operation of mitral valve replacement with Starr-Edwards model 6120 and Kay-Shiley bioprosthetic tricuspid valve replacement (08.18.1968), at the Niguarda Hospital De Gasperi Center of Milan. At 38 years she was operated of hysterectomy due to uterus cancer. At 39 years of age, she was reoperated for implantation of Carpentier n°34 bioprosthetic valve (03.12.1984) due to structural tricuspid valve deterioration. At 50 years old a pacemaker VVI for atrial fibrillation and atrioventricular block was implanted (02.04.1995). When she was 52 years old, a second structural tricuspid valve deterioration (stenosis) was found (03.09.1997); subsequently, at 59 years, coronarography was performed, showing normal coronary arteries, and then the bioprosthetic tricuspid valve was replaced with a Carpentier -Edwards n°29 prothesis (05.06.2004).
At follow-up (08.07. 2007) after 39 years of mitral valve replacement, the patient has a normal life, with NYHA functional class II; BNP is 52 ng/ml, no haemolysis nor ball variance is present. The patient has good compliance with warfarin-therapy, obtaining a convenient level of anticoagulation; in our specialist anticoagulation clinic 76% time was spent within the INR target 3-4.5 without symptomatic embolism or major bleeding. On auscultation a loud opening click is present, followed by multiple diastolic clicks of variable intensity produced by the ball bouncing in the cage; a flow systolic murmur is also present in the aortic position, produced by turbulence in the left ventricular outflow tract; a less intense click occurs with the closing of the valve.
A thirty-nine-year survival with the Starr-Edwards mitral valve prosthesis
Electrocardiogram shows atrial fibrillation and a pacemaker VVI correctly functioning. At chest x-rays severe biatrial enlargement is present, and the support ring and the cage are well seen ( fig. 1 ).
Two-dimensional and M-mode echocardiogram shows a ball-in-cage Starr-Edwards prosthesis in mitral position of normal appearance, with the cage strut echoes and the anterior echo of the ball which opens moving toward the cage in diastole and closes in systole. A severe left atrial enlargement is evident ( fig. 2 ). Colour-Doppler examination at prosthetic level typically shows multiple peripheral diastolic flow jets coming laterally from the cage and the ball. Continuous-wave Doppler study at the level of prosthetic flow shows the typical curve compatible with a well functioning prosthesis, with a moderate early diastolic gradient, a mild mean gradient and a mildly decreased functional prosthetic area, within normal limits for this type of prosthesis ( fig. 3) [4] . 
Comment
Long term survival of the individual patient is the primary goal of cardiac valve replacement. The SECBV has proved it exceptional longevity. The excellent record of valve performance in our patient is demonstrated by the fact that she survived 39 years after mitral valve replacement with SECBV, despite two subsequent reoperations for dysfunction of tricuspid valve bioprosthesis. In the literature there is no evidence of durability of this prosthesis longer than 35 years (5-6). Our patient after 39 years of mitral valve replacement lives a happy and fulfilling life (NYHA II), with no evidence of hemolysis, ball variance, symptomatic embolization or major bleeding.
Godje et al. [5] showed a survival rate at 10-20-30 years of 75%, 36%, and 23%, respectively; freedom from all valve-related complications, reoperations, and valve related death was 73%, 35%, and 14%, respectively; notably 76% of the surviving patients was in NYHA class I and II at follow-up. Finally, De Santo et al. [6] recently confirmed the satisfactory durability of the SECBV over a long-period (27-year) with a retrospective study of 440 patients with isolated Starr-Edwards-mitral valve prostheses implanted after January 1974. The mortality at 30-day was 13%. Mean follow-up was 5.157 years per patient, the mean observation time was 12±8 years. Long-term mortality was 36%; 64% of the deaths were cardiac (and 64% of them were valve-related). Long-term survival at 1,5,10,15,20, and 25 years was 94%, 87%, 76%, 68%, 57%, and 53%, respectively. No primary mechanical failures was observed. The risk of complications and the survival rate of mitral prosthetic replacement depend on left atrial size, cardiac index, the presence of coronary heart disease and left ventricular ejection fraction.
The longevity of caged ball can be excellent. In fact, almost the only concern about its long-term performance relates to the possibility of alteration in the ball poppet itself, a change known as "ball variance ". The incidence of poppet degeneration was very low in mitral position.
In the registry of Godje et al. [5] , the transvalvular gradient was between 9 and 30 mmHg; 68% showed no echocardiographic peculiarities and the left ventricular function was normal in 64%. Thrombotic occlusion of the ball valve results from gradual stenosis of the orifice by pannus "ingrowth".
Patients with caged-ball valves carry a high risk of thromboembolism and require more intensive anticoagulation therapy (INR >4). In the Auckland study thromboembolic events occurred in 45% within 5 years, compared to 13% with bioprosthetic valves (p = 0-0001), 39% having long-term sequelae. The risk of late thromboembolism is approximately 4,5 events per 100 patients-year for patients that underwent operation from 1963 to 1971 [7] .
In our patient prosthetic valve is well functioning after 39 years, as confirmed by echocardiographic data, with a moderate early diastolic gradient (17 mmHg), a mild mean diastolic gradient (8 mmHg) and a "functional" prosthetic area of 1.7 cmq. No symptomatic embolization or major hemorrhage were documented, thanks to an appropriate management of the anticoagulation therapy. The traditional management of oral anticoagulation is full of difficulties. Alternative models are therefore prospected (anticoagulant clinic, computerized software decision, portable coagulometer, self management). These new strategies can improve therapeutic control of oral anticoagulation [8] .
In conclusion, the development of the StarrEdwards heart valve marked a new era in the treatment of valvular heart disease, and has dramatically altered the natural history of patients with valvular heart disease. The Starr-Edwards valve is rarely used today. At present, there is no single "ideal "valve that is appropriate for every single patient. Heart valve have come a long way, but we are proud to say that the Starr-Edwards valve's longevity is still the gold standard against which all others are compared [9] . Despite these glowing remarks the World Congress suggested us to recall the words of Paton and Vogel regarding the "perfect valve" that has yet to be realized. We may never have definitive results. At best, we may be able to say to patients. [10] . In addressing these needs or otherwise meeting the challenge of sustained valve performance without thromboembolic risk, future solutions will probably combine more accurate computational tools that capture the complex environment of the prosthesis with molecularly engineered materials that have enhanced functionality and are assembled through microfabrication techniques. All of these developments will further the evolution of an advanced generation of heart-valve replacements whose form and function blur the distinction between the synthetic and the biologic [2] . 
Riassunto

